Literature DB >> 17388970

The protein load of therapeutic botulinum toxins.

A Pickett, R O'Keeffe, N Panjwani.   

Abstract

Mesh：

Substances：

Year:  2007        PMID： 17388970     DOI： 10.1111/j.1468-1331.2007.01683.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  7 in total

Review 1.  Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence.

Authors:  Roberta Ravenni; Domenico De Grandis; Alberto Mazza
Journal:  Neurol Sci       Date:  2013-04-11       Impact factor: 3.307

2.  Onabotulinumtoxin type A (Botox(®)) versus Incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial.

Authors:  A Campanati; K Giuliodori; E Martina; A Giuliano; G Ganzetti; A Offidani
Journal:  J Neural Transm (Vienna)       Date:  2013-09-20       Impact factor: 3.575

3.  [Botulinum toxin in dermatology].

Authors:  W G Philipp-Dormston
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

Review 4.  AbobotulinumtoxinA: A 25-Year History.

Authors:  Gary D Monheit; Andy Pickett
Journal:  Aesthet Surg J       Date:  2017-05-01       Impact factor: 4.283

Review 5.  Immunogenicity of botulinum toxins.

Authors:  Markus Naumann; Lee Ming Boo; Alan H Ackerman; Conor J Gallagher
Journal:  J Neural Transm (Vienna)       Date:  2012-09-25       Impact factor: 3.575

6.  OnabotulinumtoxinA and AbobotulinumtoxinA Dose Conversion: a Systematic Literature Review.

Authors:  Khashayar Dashtipour; Jack J Chen; Alberto J Espay; Zoltan Mari; William Ondo
Journal:  Mov Disord Clin Pract       Date:  2015-10-12

Review 7.  Botulinum Toxin in Aesthetic Medicine: Myths and Realities.

Authors:  Jeffrey S Dover; Gary Monheit; Mark Greener; Andy Pickett
Journal:  Dermatol Surg       Date:  2018-02       Impact factor: 3.398
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.